FDA OKs Phase 2 Trial of Oral NE3107 in Easing Inflammation
The launch of a Phase 2 trial into the safety and early efficacy of oral NE3107 in treating Parkinson’s disease patients with motor fluctuations while on levodopa was approved by the U.S. Food and Drug Administration (FDA), BioVie, the therapy’s developer, announced. BioVie plans to initiate patient enrollment for the trial,…